

Call for Poster Abstracts

Dear Colleague:

Posters are an opportunity for presenting late-breaking results, ongoing research, and work in progress and are intended for authors and participants to engage in discussions about their work. We encourage you to submit your work to be presented in a Poster Session at the ELN Frontiers Meeting 2012 to foster scientific exchange amongst participants and faculty. Your accepted abstract will be published in a special edition of the ELN Newsletter and posters will be displayed in a poster walk. As many as 24 abstracts will be selected for 10-minute oral presentations in three parallel sessions covering CML, CMN and AML/MDS. The ELN will cover travel and registration to attend the ELN Frontiers Meeting of the first author or designate of all accepted poster abstracts.

Rüdiger Hehlmann and Michele Baccarani

CALL FOR POSTER ABSTRACTS: European LeukemiaNET annual ELN Frontiers Meeting

The POSTER abstract submission deadline is July 30, 2012.

The Scientific Programme Committee invites you to submit abstracts for the **POSTER SESSIONS** that will be held at the ELN Frontiers Meeting 2012.

The poster sessions will provide you with an excellent opportunity to display and present your research work and to exchange ideas with fellow physicians and researchers. Authors of the ten highest ranked abstracts in each topic area will have the opportunity to present their research in a 10-minute oral presentation at the ELN Frontiers Meeting on 10-11 November 2012. All accepted abstracts will be printed in a special edition of the ELN Newsletter.

Abstracts can be submitted under the following disease areas:

- Chronic Myeloid Leukaemia (CML)
- Chronic Myeloproliferative Neoplasms (CMN)
- Myelodysplastic Syndromes (MDS) / Acute Myelogenous Leukaemia (AML)

We welcome all original research in the fields of CML, CMN, MDS and AML. The poster session may include, but will not be limited to some suggested topics as follows:

CML

- Molecular pathogenesis
- Molecular response
- Prognostic value, mutations, and/or methods
- Cytogenetics: variant translocations, FISH vs. CBA, CCA/Ph+ and CCA/Ph-
- Registry data
- Treatment discontinuation
- Long-term complete remissions
- Age: children and very old
- Interferon-alfa
- Switch: early and late switch of treatment (from imatinib to 2nd generation TKI)
- Other targeted agents: stem cell agents, HDAC inhibitors, etc.
- Preclinical and clinical data

CMN

- Molecular pathogenesis
- Pathology
- Targeted agents, preclinical and clinical data
- Therapy: Long term outcomes
- Therapy: Complications
- Interferon alfa,
- JAK inhibitors
- Stem Cell transplantation
- Registry data

AML / MDS

- Age: Children and very old
- Targeted therapy
- FLT3 inhibitors, preclinical and clinical data,
- Molecular pathogenesis
- Minimal residual disease
- Iron: Turnover, absorption, elimination, storage

ABSTRACT SUBMISSION

Presenting authors will receive a confirmation of acceptance for poster presentation and the ten highest ranked abstracts will be selected for oral presentation. Please review the attached submission guidelines for further details.

Abstracts must be submitted online at <https://events.sannet.ch/elN/>. Please use the following login information:

User name: iozdc\eln2012
Password: Submit4ELN!

We are looking forward to receiving your abstracts!

Best regards,

The Scientific Programme Committee

ELN Frontiers Meeting
10-11 November 2012, Istanbul, Turkey